Pomerantz Law Firm Investigates Potential Securities Fraud at Astrana Health (ASTH)
Pomerantz LLP has launched an investigation into Astrana Health, Inc. (NASDAQ: ASTH) following allegations of securities fraud and unlawful business practices. The probe follows a short report released by Glass House Research on September 17, 2026, which questioned the company's growth model. The short report alleged that Astrana’s expansion is driven by aggressive acquisitions and subjective management estimates rather than organic growth. Additionally, concerns were raised regarding a $545 million related-party loan and potential regulatory exposure concerning Medicare in 2027. Following these allegations, ASTH shares dropped 9.02% to close at $34.30.
Tickers: $ASTH
Topics: class action lawsuit securities fraud investigation short report stock price decline
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Potential Securities Fraud at Zscaler, Inc. (3 articles)